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Hyper- and hypo- nutrition studies 
of the hepatic transcriptome and 
epigenome suggest that PPARα 
regulates anaerobic glycolysis
Anthony R. Soltis  1, Shmulik Motola1, Santiago Vernia2, Christopher W. Ng1, Norman J. 
Kennedy2, Simona Dalin  1, Bryan J. Matthews1, Roger J. Davis2 & Ernest Fraenkel1
Diet plays a crucial role in shaping human health and disease. Diets promoting obesity and insulin 
resistance can lead to severe metabolic diseases, while calorie-restricted (CR) diets can improve health 
and extend lifespan. In this work, we fed mice either a chow diet (CD), a 16 week high-fat diet (HFD), 
or a CR diet to compare and contrast the effects of these diets on mouse liver biology. We collected 
transcriptomic and epigenomic datasets from these mice using RNA-Seq and DNase-Seq. We found that 
both CR and HFD induce extensive transcriptional changes, in some cases altering the same genes in the 
same direction. We used our epigenomic data to infer transcriptional regulatory proteins bound near 
these genes that likely influence their expression levels. In particular, we found evidence for critical roles 
played by PPARα and RXRα. We used ChIP-Seq to profile the binding locations for these factors in HFD 
and CR livers. We found extensive binding of PPARα near genes involved in glycolysis/gluconeogenesis 
and uncovered a role for this factor in regulating anaerobic glycolysis. Overall, we generated extensive 
transcriptional and epigenomic datasets from livers of mice fed these diets and uncovered new 
functions and gene targets for PPARα.
Diet plays a significant role in shaping human health and disease. Over nutrition leading to obesity can induce 
insulin resistance, a major human health concern that promotes the development of type 2 diabetes and some 
cancers1–3. In contrast, caloric restriction can extend lifespan, improve insulin sensitivity, and delay the onset of 
age-related diseases, such as diabetes, cardiovascular disease, and neoplasia4, 5. While the broad contrasts between 
high-fat diet feeding and calorie restriction are well established, the underlying molecular processes that drive 
these physiological and metabolic differences are incompletely understood.
The liver is a critical regulator of metabolism and is sensitive to dietary changes. The liver maintains normal 
glucose homeostasis by suppressing hepatic gluconeogenesis in response to insulin following feeding, while pro-
moting glucose production during fasting6, 7. High-fat diet induced obesity and insulin resistance disrupts these 
hepatic mechanisms and promotes hyperglycemia8. Caloric restriction, however, lowers liver fat accumulation 
and improves hepatic glucose regulation in obese humans9, 10 and reduces the expression of stress and inflamma-
tory genes in mouse livers, which may contribute to the anti-aging effects associated with this diet11. The liver, 
therefore, is a critical driver of the body’s response to dietary challenges. Thus, analysis of hepatic responses to 
dietary extremes may enhance our understanding of how diet shapes overall human health.
In this study, we profiled transcriptional and epigenomic landscapes in the livers of mice fed either a standard 
laboratory chow diet (CD), a long-term (16 week) high-fat diet (HFD) to induce obesity and insulin resistance, 
or a nutrition-restricted diet to model caloric restriction (CR). Overall, we present a comprehensive analysis of 
diet-induced effects on mRNA expression and chromatin accessibility in the mouse liver following HFD and CR. 
We found that calorie restriction and high fat feeding have common and independent epigenetic and transcrip-
tomic signatures. We also show that PPARα activation underlies both extreme metabolic situations and identify 
new PPARα targets that regulate glucose metabolism.
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Results
High-fat diet and calorie restriction induce extensive changes in hepatic gene expression. We 
examined mice following a long-term (16 week) high-fat diet (HFD) or a calorie restricted (CR) feeding protocol. 
As anticipated, mice fed a HFD gained body mass while CR mice lost mass compared to chow diet (CD)-fed con-
trols (p < 5e-5, two-sided t-tests) (Fig. 1A). We assessed glucose homeostasis in HFD mice compared to controls 
Figure 1. High-fat diet and calorie restriction alter body mass and induce extensive hepatic transcriptional 
changes. (A) HFD and CR feeding increase and decrease overall mouse body mass, respectively, compared 
to CD (n = 12, 10, and 12 for CD, HFD, and CR, ***p < 5e-5, two-sided t-tests). (B–D) HFD induces insulin 
resistance and alters glycemic regulation as assessed by (B) glucose tolerance test (GTT), (C) insulin tolerance 
test (ITT), and (D) pyruvate tolerance test (PTT) (p-values from t-tests of area under the curve measurements, 
n = 30, 25, and 23 for CD and n = 37, 27, and 23 for HFD). (E) Venn diagrams show numbers of genes 
differentially expressed between CD and HFD livers (red circle) as well as CD and CR livers (blue circle). The 
overlap region shows 695 genes that are differentially expressed in both CR and HFD compared to CD. The 
clustergram shows these 695 overlapping genes that are up-regulated by both HFD and CR (255 genes), down-
regulated by both CR and HFD (183 genes), up-regulated in HFD and down-regulated by CR (186 genes), and 
up-regulated in CR but down-regulated in HFD (71 genes), along with gene ontology and pathway enrichment 
terms. The numbers indicate how many genes in each group that are annotated to each term. Values are log2 
fold-changes for individual replicate expression levels (in FPKM) versus the mean CD expression level. (F) 
3,901 genes are differentially expressed between CR and HFD livers (green circle). The clustergram shows 
individual replicate gene expression levels as log2 fold-change compared to the mean expression level for the 
opposite condition (CR or HFD). The numbers indicate how many genes in each group that are annotated to 
each term.
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using tolerance tests for glucose (GTT, Fig. 1B), insulin (ITT, Fig. 1C), and pyruvate (PTT, Fig. 1D) and confirmed 
that mice fed a HFD are strongly insulin resistant and glucose intolerant.
We comprehensively quantified the hepatic transcriptomic landscapes of these mice using RNA-Seq (Fig. S1B 
and Table S1). Both HFD and CR induced widespread changes in hepatic gene expression compared to CD, 
with 2,830 and 2,724 genes differentially expressed by the two conditions, respectively (FDR < 0.05, absolute log2 
fold-change > 0.5) (Fig. 1E). HFD induced the expression of genes involved in immune responses (FDR < 6.4e-
22, e.g. Ccr1, Ccr2, Cd36, Tlr1), lipid metabolism (FDR < 8e-6, e.g. Abcd1, Apoa4, Cyp17a1, Srebf1, Thrsp), stress 
responses (FDR < 1.3e-5, e.g. Anxa1, Axl, Car3, Hif1a, Jak2), and cell death (FDR < 6e-4, e.g. Bak1, Casp7, Jun), 
among others. CR up-regulated genes are involved in cholesterol metabolism (FDR < 2.5e-11, e.g. Cebpa, Dhcr7, 
Hmgcr, Ldlr) and mitochondria (FDR < 7e-7, e.g. Atp5e, Cox5a, Mrps24), among other processes.
We found a significant set of 695 genes (p < 3.6e-14, hypergeometric test of 695 overlapping genes) that are 
differentially regulated by both HFD and CR compared to CD, including 255 genes up-regulated by both HFD 
and CR, 183 down-regulated by both, 186 up-regulated in HFD and down-regulated by CR, and 71 up-regulated 
in CR but down-regulated in HFD (Fig. 1E and Table S1). Of note, the majority of these genes (438 or ~63%) 
change in the same direction compared to CD (p < 2e-14, Fisher’s exact test). The first set of genes (up-regulated 
in both conditions) is enriched in processes related to oxidation-reduction (FDR < 0.004) and lipid metabolism 
(FDR < 0.021). This latter category includes genes involved in cellular fatty acid synthesis (e.g. Fads1, Fads2, 
Fasn, Scd1), lipid and cholesterol production (Dhcr24, Nsdhl, Srebf1), triglyceride synthesis (Thrsp), and perox-
isomal import of free fatty acids (Abcd1, Abcd2). We note that expression changes in oxidation-reduction and 
lipid metabolism in CR mice are not a consequence of any increases in consumed dietary fat content, as the CR 
diet contains a similar percentage fat content to the CD and because CR mice consumed overall less food, and 
therefore less fat, than both the CD and HFD mice. The second set of overlapping genes (down-regulated in 
both conditions) is enriched in organonitrogen catabolism (FDR < 0.02, e.g. Aass, Agxt, Cbs, Kynu, Pnp). Genes 
up-regulated by HFD but down-regulated by CR are involved in immune response (FDR < 6.9e-8, e.g. Apoa4, 
C1qa,b,c, Gas6) and inflammation (FDR < 6.5e-3, e.g. Aif1, Axl, Csf1, Tgfb1), while genes up-regulated by CR but 
down-regulated by HFD compared to CD are involved in translation and ribosomal composition (FDR < 0.019, 
e.g. Rpl37, Rps15a, Rps28, Rps3). This analysis highlights a common set of genes altered by both conditions that, 
in a majority of cases, are altered in the same way, a surprising result given the differences in the overall metabolic 
states of CR and HFD mice.
We next compared the CR and HFD liver RNA-Seq samples to directly contrast the two dietary extremes. We 
found in total 3,901 differentially expressed genes, with 1,857 genes up-regulated in HFD and 2,044 up-regulated 
by CR (Fig. 1F and Table S1; Fig. S1A for qPCR validation of select genes). Similar to our other comparisons of 
the gene sets altered by these diets, genes up-regulated by CR are enriched in processes related to ribosomes, 
mitochondria, translation, and tRNA processing, while HFD-induced genes are enriched in immune responses, 
extracellular matrix components, and cell death. Thus, although we found evidence for genes regulated similarly 
following CR and HFD (Fig. 1E), in general these two dietary extremes induce distinct gene expression programs.
DNase-Seq and motif analyses identify PPARα and RXRα as common regulators of HFD and 
CR-induced gene expression in liver. Given the widespread hepatic transcriptional changes induced by 
both HFD and CR feeding, we performed DNase-Seq on the livers of CD, HFD, and CR mice in order to uncover 
accessible regulatory regions throughout these genomes that likely harbor regulatory proteins associated with 
the transcription of these differential genes. Globally, we found high correlations (r = 0.76–0.84) between hyper-
sensitive regions identified in the livers of the mice on the three diets (Fig. S2A–C). For subsequent analyses, we 
merged the regions identified in all three diets into a set of 92,626 total hypersensitive sites to maximize the search 
space for regulators (Fig. 2A). We mapped each of these regions to known gene coordinates within the mouse 
genome and found that the majority of these regions reside within introns (41%). Additional near-gene sites 
include: proximal promoters (12%), distal promoters (9%), sites downstream of gene bodies (8%), coding exons 
(3%), 5′ UTRs (3%), and 3′ UTRs (1%). The remaining sites map to distal intergenic regions linearly distant from 
known gene boundaries (23%). Thus, the majority (77%) of identified hypersensitive regions appear in or near 
annotated gene boundaries throughout the mouse genome.
As specific examples, we found hypersensitive regions across the conditions near the gene Cyp2b10, which is 
a known target of the nuclear hormone receptors CAR and RXR12, 13 (Fig. S2D). Additionally, we found a number 
of hypersensitive sites near and within the introns of the gene Abca1, which is a known target of RXR and LXR in 
the liver14 (Fig. S2E). We performed direct motif analysis on the hypersensitive regions near these select genes and 
indeed found enrichment for the RXR:LXR motif (Fig. S2F). Thus, the use of motif analysis on the hypersensitive 
regions near genes altered by diet could reveal regulators associated with these changes.
We examined the discovered DNase hypersensitive regions near the transcription start sites (TSSs, +/−10 kb 
for this analysis) of our differential gene sets for enriched transcriptional regulator motifs (Fig. 2B and Table S2). 
We divided the hypersensitive sites near these gene sets into low (<0.5) and high (>0.5) CpG content sequences 
and assessed motif enrichment in both sets of sequences (see Methods). We found distinct motif enrichments in 
low versus high CpG content hypersensitive sequences, but consistently observed nearly the same motif enrich-
ments (and rankings) across all the gene sets for the two sets of sequences. In low CpG content regions, we 
observed strong enrichments near all the gene sets for nuclear hormone direct repeat 1 motifs, corresponding 
to the factors PPARα, PPARγ, RXRα, and HNF4α, as well as ATF/CREB, HNF1 dimer (HNF1α and HNF1β), 
FXR:RXR inverted repeat, fork head factor (FOXA, FOXO, FOXJ, FOXK, etc. factors), and nuclear factor 1 dimer 
(NFIA, NFIB, NFIC, and NFIX) motifs (Fig. 2C). In high CpG content regions, we also observed motif enrich-
ment for ATF factors, though with more preference for thymine as opposed to guanine in the second position 
of the motif (ATF, HLF factors), as well as dimeric nuclear respiratory factor (NRF1), ELK/ETS/ETV, E2F (E2F 
and DP-1 factors), AHR/EGR, and heterotrimeric transcription factor (NFYA, NFYB, NFYC) motifs (Fig. 2D). 
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We only found modest enrichments for factors when comparing conditions against one another, e.g. low CpG 
content regions near up-regulated genes in CR versus regions near genes up-regulated in HFD. This observation 
is likely due to the fact that we saw such strong enrichments for the same factors in low and high CpG content 
regions regardless of the gene sets tested. Thus, these factors likely play multiple roles in different contexts to 
regulate the gene expression programs we observed across the various diets. Given the strong enrichment for 
nuclear hormone receptor motifs in the low CpG content regions we analyzed, we chose to investigate further the 
genome-wide binding profiles for the factors PPARα and RXRα to examine their roles in regulating CR and HFD 
hepatic gene expression.
ChIP-Seq profiling of PPARα and RXRα binding in CR and HFD livers reveals extensive 
genome-wide regulation and uncovers novel targets. Our motif analysis strongly suggested that 
PPARα and RXRα, two transcription factors prominently expressed in liver15, 16, contribute to the differential 
expression of genes in the livers of mice fed either a high fat or calorie restricted diet. We also found significant 
enrichment for a set of 228 known PPARα target genes among all the differential genes (hypergeometric p-values 
<5e-4)17. For example, 27 of the 695 genes differential in both CR and HFD livers compared to CD (Fig. 1E) are 
among this set of known PPARα targets (p < 3.7e-7). We thus used ChIP-Seq with specific antibodies against 
these factors (Fig. S3A) to profile their genome-wide binding profiles in CR and HFD livers.
As anticipated from our motif analyses, our ChIP-Seq datasets confirmed that both PPARα and RXRα bind 
extensively near genes in these livers (Fig. S3B and Table S3). Overall, we detected more RXRα binding than 
PPARα, likely due to the lower obtained sequencing depth from PPARα samples. Over all binding sites for each 
factor, we detected some form of the PPAR:RXR heterodimer motif (direct repeat 1) in 91% and 90% of PPARα 
and RXRα regions, respectively; thus, the majority of identified binding sites contain an expected motif for these 
factors, though ~10% of these sites likely reflect alternative binding mechanisms (e.g. via other DNA-binding 
co-regulatory proteins). PPARα binding sites mapped to 1,253 and 2,320 annotated genes in CR and HFD, 
respectively, while RXRα enriched regions mapped 3,381 and 4,767 genes (+/−10 kb window). The genome-wide 
binding distributions for these factors also closely mirror those observed in our DNase-Seq experiments, with 
the majority of binding regions located in introns (42–44%) as well as other near-gene regions (Fig. S3B, left and 
middle columns). 23–32% of all binding sites were classified as distal intergenic. We also searched for regions in 
which we found proximal binding events for both factors (peak summits within +/−100 bp) and found 2,831 and 
8,838 such regions in CR and HFD livers. The genome-wide binding locations for these regions were similar to 
those observed for the individual factors (Fig. S3B, right column).
Figure 2. DNase-Seq reveals regulatory regions across liver genomes and motif analyses identify potential 
transcriptional regulators. (A) We found 92,626 hypersensitive regions among CD, HFD, and CR livers. The 
majority of identified sites reside within annotated gene introns (41%) as well as other near-gene locations. 
Regions were mapped near genes according to: proximal promoters – within 200 bp of gene TSS; distal 
promoters – within 5 kb upstream of gene; downstream – within 5 kb downstream of gene end; introns, exons, 
5′ UTR, and 3′ UTR – if region intersected one of these features; and distal intergenic – outside 5 kb window 
around gene. (B) The numbers of identified hypersensitive regions near differential gene sets (first column) 
within +/−10 kb of gene transcription start sites (TSS) in low (middle column) and high (right column) CpG 
content sequence sets are presented. (C,D) The most enriched DNA binding motifs (see Table S2) near all gene 
sets are shown for low (C) and high (D) CpG content sequences.
www.nature.com/scientificreports/
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We used the uncovered binding events to identify known and novel genes that are likely regulated by these fac-
tors. PPARα, typically bound as a heterodimer with RXRα, is a well-characterized regulator of lipid metabolism18, 
and we saw strong enrichment for such metabolic processes in up-regulated genes in both CR and HFD livers 
(Fig. 1E). Consistent with this, we identified binding events near the transcription start sites of genes involved 
in various lipid metabolic processes which are known to be regulated by PPARα/RXRα17, including Acadl 
(involved in mitochondrial β-oxidation), Cpt2 (involved in mitochondrial oxidation of long-chain fatty acids), 
Fabp1 (involved in fatty acid uptake and transport), and Fgf21 (involved in fatty acid oxidation and ketogenesis) 
(Fig. 3A). Among these, we found binding evidence for both PPARα and RXRα near Fgf21 in HFD only (Fig. 3A, 
bottom right). This result is consistent with our RNA-Seq data in that Fgf21 is up-regulated in HFD livers com-
pared to CR (log2 fold-change of 2.9, FDR < 4.5e-7).
Our analyses identified several novel targets of PPARα and RXRα, including Crtc2 and Nfic (Fig. 3B). Crtc2 
is a known co-regulator of glucose metabolism19. We identified binding events for both factors across the two 
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Figure 3. ChIP-Seq of PPARα and RXRα transcription factors in CR and HFD livers reveals extensive binding 
near known and novel regulated genes. (A) The binding profiles (+/−5 kb gene TSS) for known PPARα 
and RXRα targets Acadl, Cpt2, Fabp1, and Fgf21 in CR and HFD livers are shown. (B) The binding profiles 
(+/−5 kb gene TSS) for novel PPARα and RXRα targets Crtc2 and Nfic in CR and HFD livers are shown. 
(C) The binding profiles for PPARα near the differentially expressed genes Abcc4 and Cyp7a1 (CR vs. HFD) 
that contain differential binding events between the same two diets in our ChIP-Seq data. Arrows indicate 
differential binding regions; N.S. stands for not significant. Read pileup refers to extended, normalized, and 
smoothed read pileup counts extracted from concatenated pools of aligned reads for the biological replicates 
for each factor (see Methods). Green lines indicate significantly called peaks in both CR and HFD. Red and blue 
lines indicate significantly called peaks in HFD and CR, respectively.
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diets at the promoter of this gene. We also highlight binding near Nfic, a gene also up-regulated in HFD livers 
compared to CR, which has up-stream binding events for PPARα in HFD only, as well as clear binding peaks for 
RXRα alone at its TSS in both CR and HFD. Thus, our profiling of PPARα and RXRα in CR and HFD-fed mouse 
livers revealed binding events near many genes known to be regulated by these factors, while also uncovering new 
genes not previously characterized as targets of these factors.
Finally, we tested our PPARα and RXRα ChIP-Seq datasets for evidence of differential binding between CR 
and HFD livers. We observed a small set of statistically significant differential binding events between the diets 
for RXRα regions (381 regions, 1.2% of total), even though we identified roughly two times as many called RXRα 
peaks in HFD compared to CR (Fig. S3B). This result is likely due to thresholding differences during binary peak 
calling (e.g. due to sequencing depth) which do not always manifest as true statistical differences when comparing 
read counts in these regions directly. 112 of these 381 differential peaks mapped within +/−20 kb of 103 differen-
tial genes between CR and HFD livers. We saw more evidence for differential binding of PPARα between CR and 
HFD, with 1,201 (9.3% of total) identified peaks showing significant differential enrichment. Only 307 of these, 
however, mapped to a gene differentially expressed between CR and HFD, covering 284 of the nearly 4,000 poten-
tial differential genes. Among these, we observed a differential peak ~10 kb upstream of the Abcc4 gene promoter 
that shows lower enrichment in HFD compared to CR (Fig. 3C, left). Indeed, Abcc4 is expressed significantly 
lower (~−1 log2 fold-change) in HFD compared to CR in our RNA-Seq data. As another example, we found a 
differential peak with higher enrichment in CR within the gene body of Cyp7a1, which is also expressed higher 
in CR compared to HFD by RNA-Seq (Fig. 3C, right). Though we did not detect many differential binding events 
near these genes, we did detect many binding events in general for these factors near a substantial number of the 
differential genes. 4,060 PPARα sites map to 1,879 of these genes and 10,271 RXRα peaks map to 2,994. Thus, we 
found specific instances of differential PPARα and RXRα binding near differential genes between CR and HFD, 
though such differences only explain small fractions of the total differential gene pools. These results suggest that 
these factors, given that they indeed bind near many of the differential genes even if the degrees of binding do not 
measurably change, regulate gene expression differences by mechanisms other than differential binding (e.g. due 
to differential activity levels or co-factor/co-repressor binding events), though some genes may be more sensitive 
to differential binding events by other factors.
mRNA expression, binding data, and fenofibrate-treated primary hepatocytes further suggest 
a role for PPARα in regulating glucose metabolism. While PPARα has extensively been characterized 
as a regulator of lipid metabolism, there is evidence that this transcription factor plays a role in regulating glucose 
metabolism17, 20–22. In particular, PPARα knock-out mice show severe hypoglycemia and depleted hepatic glyco-
gen stores during fasting23. Moreover, PPARα has been shown to regulate the gluconeogenic genes G6pc, Pck1, 
and Pcx, the glycerol converting genes Gpd1 and Gpd2, and the pyruvate dehydrogenase inhibitor Pdk417, 22, 24. 
Indeed, we detected PPARα binding events near the transcription start sites or within the bodies of these genes.
We examined genes in the canonical gluconeogenesis/glycolysis pathway for evidence of PPARα binding and 
found events near nine genes (of fourteen queried) encoding enzymes in this pathway (Fig. 4A). Interestingly, 
we found that Aldob, Fbp1, Fbp2, Pck1, and Pklr not only bind PPARα, but are sensitive to PPARα activation20 
(Fig. 4A, blue highlighted genes). Furthermore, our RNA-Seq data demonstrate PPARα-bound genes are regu-
lated by feeding a HFD or CR, including Gck and Pklr that are up-regulated by CR and HFD, G6pc and Gapdh that 
are down-regulated by CR, and Eno3 that is down-regulated in HFD (Fig. 4A, colored bars). Thus, PPARα likely 
influences diet-induced expression changes of these genes.
To further test the role of PPARα in regulating hepatic glucose metabolism, we treated mouse primary hepato-
cytes with fenofibrate, a PPARα agonist, and measured glycolytic rates. PPARα activation in hepatocytes cultured 
with glucose as a fuel displayed a significant increase in lactate production, suggestive of an increase in glycolytic 
flow (Fig. 4B). Consistent with this result, we observed decreased glucose production in the presences of lactate/
pyruvate as a gluconeogenic source in fibrate-treated hepatocytes (Fig. 4C). These results suggest that PPARα 
enhances glycolysis, leading to non-oxidative conversion of glucose to lactate. To test this hypothesis, we assessed 
the oxygen consumption rate (OCR) in primary hepatocytes using glucose as a fuel (Fig. 4D). OCR was consist-
ently lower in fenofibrate-treated hepatocytes, even in the presence of oxygen consumption inhibitors (oligomy-
cin and rotenone) and enhancers (FCCP). We observed reduced basal OCR (Fig. 4E) and maximal respiratory 
capacity (Fig. 4F), as well as lower ATP turnover (Fig. 4G), in fenofibrate-treated primary hepatocytes compared 
to vehicle controls, confirming that PPARα activation decreases oxidative metabolism of glucose. These results, 
together with our binding data and RNA-Seq results in CR and HFD livers, further stress a role for PPARα in 
regulating glucose metabolism.
In vivo fenofibrate treatment confirms role of PPARα regulation near genes involved in glucose 
metabolism in liver. We next tested the effect of in vivo fenofibrate treatment on specific PPARα targets 
identified by our ChIP-Seq data. We treated mice for two weeks with either vehicle or fenofibrate and meas-
ured hepatic gene expression of PPARα targets using quantitative PCR. We found significant up-regulation of 
well-characterized PPARα target genes following fibrate treatment, including Acox1, Ehhadh, and Pdk4 (Fig. 5A). 
We next tested several novel PPARα targets identified from our ChIP-Seq data analysis. In keeping with our 
identification of a role for PPARα in regulating glucose metabolism, we found binding sites near the genes Fbp1 
and Gck in both CR and HFD and Pklr in HFD. Following in vivo fenofibrate treatment, the expression levels 
of these genes were significantly repressed, providing further support that these are regulated targets of PPARα 
(Fig. 5B). We also tested other novel targets bound in our ChIP-Seq data, including Aldh1, Aldh2, Eno1, Pcx, and 
Sirt3; however, these were not significantly altered following fibrate treatment by qPCR, suggesting that additional 
mechanisms are necessary to control their expression in vivo.
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Discussion
In this study, we examined the hepatic transcriptional and epigenetic landscapes of mice fed chow, high-fat, and 
calorie-restricted diets. Joint analysis of our epigenetic data with regulatory protein DNA binding motif data 
revealed a common set of transcription factors that may regulate the genes altered by these diets. In particular, we 
found strong enrichments for the PPARα and RXRα motifs near all the identified differential gene sets. We fur-
ther investigated these findings with direct ChIP-Seq experiments for these factors and found that they do indeed 
bind extensively near these genes throughout the genomes of HFD and CR mice, further suggesting extensive 
roles for these factors in the hepatic response to dietary challenges. We particularly focused on the role of PPARα 
in regulating glucose metabolism in the liver and found extensive binding near genes encoding proteins involved 
in metabolism of carbohydrates. We validated these findings by treating primary mouse hepatocytes with fenofi-
brate to stimulate PPARα activation, discovering that activation of this factor enhances anaerobic glycolysis. We 
also performed in vivo fenofibrate treatment experiments in mice and, using quantitative PCR, validated several 
Figure 4. PPARα binds extensively near genes involved in gluconeogenesis/glycolysis in CR and HFD 
livers and activation by fenofibrate enhances anaerobic glycolysis in primary hepatocytes. (A) Canonical 
gluconeogenesis/glycolysis pathway highlighting genes bound by PPARα (purple outline boxes) and genes 
both bound by PPARα in our dataset and sensitive to fibrate in Kane et al.20 (blue outline boxes). The two-
element color bars near the bound genes represent the log2 fold-changes in mRNA expression (by RNA-Seq) 
for these genes in HFD and CR livers, respectively, versus CD. *Indicates statistically significant changes 
(q < 0.05). (B) Lactate production in mouse primary hepatocytes following vehicle (black line) or fenofibrate 
(red line) treatment in the presence of glucose. (C) Glucose production in the presence of lactate/pyruvate 
as a gluconeogenic source following vehicle (black line) or fenofibrate (red line) treatment. (D) Oxygen 
consumption rate (OCR) assessed in the presence of glucose following vehicle (black line) or fenofibrate 
(red line) treatment. OCR also assessed following oligomycin, FCCP, and rotenone drug treatments. (E–G) 
Assessment of basal OCR (E), respiratory capacity (F), and ATP turnover (G) in primary hepatocytes following 
vehicle or fenofibrate treatment.
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novel gene targets for PPARα involved in glucose handling. Overall, we present a comprehensive analysis of the 
effects of high-fat feeding and caloric restriction on mouse hepatic transcriptomics and epigenomics, along with 
new insights into how the divergent physiological and metabolic states induced by these diets are regulated at the 
level of transcription.
Our transcriptional profiling data revealed extensive changes in gene expression induced by both HFD and 
CR compared to CD, as well as many changes between HFD and CR directly. Interestingly, we observed a signif-
icant set of 695 genes that change in both extreme diets compared to controls, with 438 of these changing in the 
same direction. Genes that are up-regulated in both HFD and CR are enriched in oxidation-reduction and lipid 
metabolic processes, while genes down-regulated in both conditions are enriched in organonitrogen catabolism. 
Our data thus suggests that some processes and pathways, e.g. fatty acid synthesis, are commonly utilized by the 
liver in response to divergent dietary challenges. To this end, HFD induces unsaturated fatty acid and triglyceride 
synthesis to accumulate fat25 while CR induces adipose and liver enzymes involved in fatty acid metabolism, 
including Fasn and Srebf1 which were significantly up-regulated by both diets in our data, to reduce oxidative 
stress and to induce energy production via β-oxidation26. Thus, the liver can co-opt specific pathways for purposes 
suitable to the needs of various external challenges, in this case dietary changes.
The majority of transcriptional changes induced by HFD and CR, however, are divergent. Specifically 
up-regulated at the mRNA level in HFD livers are genes involved in immune responses, inflammation, extra-
cellular matrix, and cell death, consistent with anticipated complications resulting from obesity-induced insu-
lin resistance27–29. CR livers induced genes related to ribosomes, translational processes, and mitochondria. The 
inflammatory state observed in HFD livers likely maintains complications related to the insulin resistant state, 
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Figure 5. Identified targets are regulated in vivo by PPARα. (A) Read pileup profiles for CR and HFD PPARα 
ChIP-Seq near known regulated genes with corresponding in vivo qPCR results following fenofibrate treatment. 
(B) Read pileup profiles for CR and HFD PPARα ChIP-Seq near novel regulated genes with corresponding in 
vivo qPCR results following fenofibrate treatment. Read pileup refers to extended, normalized, and smoothed 
read pileup counts extracted from concatenated pools of aligned reads for the biological replicates for each 
factor (see Methods). Green lines indicate significantly called peaks in both CR and HFD. Red and blue lines 
indicate significantly called peaks in HFD and CR, respectively. *p < 0.05, **p < 0.01.
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whereas the reduction in genes associated with these processes in CR, whether compared to CD or HFD, may 
contribute to the beneficial effects of caloric restriction.
Epigenetic data from DNase-Seq experiments allowed us to map the landscapes of accessible regulatory 
regions throughout the livers of mice fed each of these diets. We found that most of these accessible regulatory 
regions reside either within or proximal to known gene boundaries (77%), with the majority residing in introns 
(41%). We used sequence analysis of these accessible regulatory regions with known DNA-binding motif pref-
erences for regulators to infer factors that are likely associated with transcription of the genes altered by diet. 
We separated sequences into low and high CpG content sets and looked for motif enrichments across several 
differential gene sets. While we did find factor enrichment differences between the low and high CpG content sets 
of sequences, as can be anticipated, we did not find many differences in motif enrichments between the various 
gene sets. These results suggest that common sets of regulatory proteins are utilized for numerous purposes in the 
liver. We identified strong enrichments for nuclear hormone receptors, ATF/CREB, and HNF1 factors in low CpG 
content regions, whereas we found nuclear respiratory factor and ELK/ETS/ETV factor enrichments in high CpG 
content regions (among others). The strong enrichment of nuclear hormone receptor factors led us to examine 
the binding profiles for some of these factors more specifically in HFD and CR livers.
We profiled PPARα and RXRα binding throughout the livers of HFD and CR mice using ChIP-Seq. Overall, 
we found extensive binding for these factors across the genomes as suggested by our motif analyses. We con-
firmed many known binding sites for these factors near the transcription start sites of specific genes, but also 
found several novel binding events near genes not known to be regulated by PPARα or RXRα (e.g. Crtc2 and 
Nfic). We also directly compared binding events for these factors between HFD and CR. Overall, we found that 
only 1.2% (381 regions) of RXRα binding sites were differential between the diets, whereas a greater percentage 
(9.3%, 1,201 regions) of identified PPARα binding sites showed some evidence for differential binding. However, 
only a small portion of these differential sites mapped near genes found to be differentially expressed between 
HFD and CR, though many of these genes do indeed possess at least some binding evidence for these factors 
within or near their boundaries. We highlighted Abcc4 and Cyp7a1 as examples of genes that change in expression 
between the diets and that also possess a differential binding region for PPARα nearby.
While PPARα is a well-established regulator of lipid metabolism in the liver18, we noted extensive binding 
for this factor near genes involved in glucose metabolism. Prior studies of PPARα mutant mice22, 30, induced 
activation of PPARα in mice20, 31, and others21, 32 have also suggested a role for PPARα-dependent regulation of 
carbohydrate metabolism. Here, we found evidence for PPARα binding near many genes specifically involved in 
the glycolysis/gluconeogenesis pathway (9 of 14 genes in the canonical pathway analyzed), many of which are sen-
sitive to PPARα agonist treatment according to prior data20 and five of which are altered in expression in response 
to HFD and/or CR according to our RNA-Seq data. To further test the role of PPARα in regulating glucose 
metabolism, we performed in vitro experiments in mouse primary hepatocytes and in vivo experiments in mice 
following fenofibrate treatment. We found that activation of PPARα by fenofibrate enhanced lactate production 
in the presence of glucose, but decreased glucose in the presence of lactate as a fuel. These results suggest a role 
for PPARα in enhancing anaerobic glycolysis in the liver. To further test these results, we showed that fenofibrate 
treatment reduces oxygen consumption rates in hepatocytes. We also found that fenofibrate treatment reduces 
the expression of the genes Fbp1, Gck, and Pklr in vivo, all of which are novel PPARα-regulated genes identified in 
this study that are involved in glucose metabolism and contain clear binding sites for PPARα near their transcrip-
tion start sites. Indeed, evidence for a regulatory role of PPARα on Gck expression is somewhat contradictory 
from previous studies22. Fibrate has been shown to decrease its expression in mouse (as we see here), though the 
PPARα agonist WY14643 does not have the same effect. Moreover, rats possess a PPAR response element (PPRE) 
near this gene that is activated by LXRα/RXRα and PPARγ/RXRα in luciferase assays, though the role of PPARα 
in such studies has not been elucidated. Here, we show that PPARα indeed binds near the liver promoter of Gck 
and that the expression of this gene is sensitive to in vivo fenofibrate treatment. Overall, our results strongly sug-
gest a role for PPARα in regulating glucose metabolism, in particular anaerobic glycolysis.
Methods
Animals and treatments. Calorie restricted male C57BL/6 J mice (5 months of age, 40% calorie restric-
tion33, 13.7% calories from fat) were obtained from Charles River Laboratories. Additional male C57BL/6 J 
mice (stock number 000664, Jackson Labs, Bar Harbor, ME) were fed a standard normal (chow) diet (Prolab 
Isopro RMH 3000, LabDiet, St. Louis, MO, 14.3% calories from fat) or a high fat diet (HFD) (TD.93075; Harlan 
Laboratories, South Easton, MA, 54.8% calories from fat) for a period of 16 weeks with free access to food and 
water. All mice used in this study were housed in a facility accredited by the American Association for Laboratory 
Animal Care (AALAC). Calorie restricted mice were acclimated in the same animal facility as the chow and HFD 
mice prior to euthanasia. All experiments were carried out in accordance with guidelines for the use of laboratory 
animals and were approved by the Institutional Animal Care and Use Committees (IACUC) of University of 
Massachusetts Medical School and Massachusetts Institute of Technology.
Glucose tolerance tests were performed by intraperitoneal injection of mice with glucose (1 g/kg). Insulin 
tolerance tests were performed by intraperitoneal injection of mice with insulin (0.5 U/kg). Pyruvate tolerance 
tests were performed by intraperitoneal injection of mice with pyruvate (1 g/kg). Assays were performed using 
methods described previously34.
We also injected 8 week old C57BL/6 male mice intraperitoneally with the fenofibrate (100 mg/kg), the PPARα 
antagonist GW6471 (10 mg/kg), or with vehicle (DMSO/Solutol HS15/Sterile water) (10:15:75) three times a 
week over a two week period.
RNA-Seq. Total RNA was extracted from the livers of mice (three per dietary condition) fasted overnight 
using the RNeasy Plus Mini kit (Qiagen, Valencia, CA). mRNA was isolated from DNA-free total RNA using an 
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Illumina mRNA Purification Kit (Illumina, San-Diego, CA). The cDNA library was size-fractionated via gel elec-
trophoresis by cutting a narrow slice (~2 mm, +/−25 bp) of the cDNA lane centered at the 300 bp marker. cDNA 
from the gel slice was extracted using the Qiagen PCR mini elute kit (Qiagen). The sample was then amplified 
by PCR using the paired-end primers and amplification reagents supplied with the Illumina ChIP-Seq genomic 
DNA prep kit. The amplified product was purified using a Qiagen PCR mini elute kit (Qiagen). The library was 
then used to build clusters on the Illumina flow cell according to the manufacturer’s protocol.
Following sequencing, the raw paired-end reads were aligned to known mouse RefSeq gene transcripts 
obtained from the UCSC table browser35 (accessed on May 19, 2016) and the mouse genome (build mm9) with 
the splice junction-aware short-read alignment tool TopHat (version 2.1.0)36. We restricted TopHat to only align 
to known transcript splice junctions. We used the Bioconductor package conditional quantile normalization 
(CQN, version 1.6.0)37 to remove systematic biases due to GC-content and gene length coverage and used DESeq2 
(version 1.0.18)38 to perform differential expression analyses. We considered a gene to be differentially expressed 
if it possessed an absolute log2 fold-change between conditions ≥0.5, an FDR-adjusted p-value (q-value) ≤0.05, 
and was expressed in at least one tested condition (i.e. ≥0.1 FPKM).
Clustering and enrichment analyses. All hierarchical clustering was performed with the clustergram 
function in Matlab with Euclidean distance and average linkage. For enrichment analyses, we used custom 
Matlab code implementing the hypergeometric distribution for enrichment p-value calculations and used the 
Benjamini-Hochberg FDR procedure to correct for multiple hypotheses.
Microarray analysis. Raw CEL files from a published microarray study were obtained from the Gene 
Expression Omnibus, accession number GSE1214720. This included data from male C57Bl/6 mice treated with 
several selective PPARα agonists for 24 hr or 5 days at 1 mg/kg/day or water (vehicle) as control. Samples were 
background adjusted and normalized using the Bioconductor package gcrma and tested for differential expres-
sion between conditions using limma39 in R.
DNase-Seq. We performed DNase-Seq on livers from mice fed CD, HFD, or CR according to a previously 
described protocol40. Briefly, liver nuclei were isolated from a pool of 3–4 mice using sucrose based buffer and 
digested with DNaseI (Promega, Madison, WI). The chromatin was incubated overnight with Proteinase K (Life 
technologies, Grand Island, NY) at 55 °C. DNA was extracted using phenol chloroform and small DNA fragments 
were isolated using a sucrose gradient ultracentrifugation followed by a gel size selection step. The DNA frag-
ments were subjected to library preparation and sequencing according to the Illumina protocol.
Sites of DNase cleavage are identified as the 5′ ends of the sequenced short reads from the DNase-Seq assay. 
We used the GPS algorithm41 to identify regions of enriched cleavage compared to a control DNase-Seq assay 
performed on naked genomic DNA (proteins stripped from the chromatin by phenol-chloroform extraction). 
GPS builds a probabilistic mixture model to predict the most likely positions of binding events at single-base 
resolution, requiring an empirical spatial distribution of DNase reads around a typical binding event to build its 
event detection model. To build the empirical distribution, we identified binding regions from PPARα and RXRα 
ChIP-Seq data in the same condition, centered in on regions containing known motifs for the protein in question, 
and summed the DNase read distribution at every base pair in a 600 base pair window around these binding 
sites. We also performed pairwise comparisons between conditions by submitting both DNase datasets to GPS in 
multiple condition mode.
Motif analyses. For DNase hypersensitive sites, we took a 100 bp window around the single base 
GPS-identified sites for calculation of CpG content and motif matching. We calculated normalized CpG content 
of sequences using42, 43:
= =Normalized CpG Observed CpGs
(Expected CpGs GC content)
Observed CpGs
(GC content/2)2
and divided sequences into low (<0.5) and high (>0.5) CpG content sets based on the bimodality of the empirical 
CpG content distribution obtained.
For motif analyses, we used a set of 1,588 DNA-binding motifs annotated to human and mouse transcriptional 
regulatory proteins from release 2013.3 of TRANSFAC® 44, represented as position-specific scoring matrices 
(PSSMs). All motifs used were of sufficient total information content (>8 total bits). We extracted the underly-
ing genomic sequences from DNase hypersensitive regions and used TAMO45 to store the motif PSSMs, read in 
sequences, and score the sequences for matches to the motifs. We computed a normalized log-likelihood ratio 
(LLR) score as LLRnorm = (LLR − LLRmin)/(LLRmax − LLRmin) for every k-base-pair sub-sequence in the region, 
where k is the length of the motif PSSM. A motif match was called if LLRnorm was greater than or equal to the 
TRANSFAC®-computed minimum false positive matrix similarity score threshold (minFP) for that motif. The 
maximum matching LLRnorm for each motif in each sequence was retained. Regions with no matches to a given 
motif were given a score of zero. We also computed motif match scores for sets of equally-sized, GC-content 
matched background sequences obtained by randomly sampling regions from the mm9 genome.
We used a hypergeometric test to determine enrichment of a motif in the sets of foreground sequences (i.e. 
DNase regions) compared to matching random background sequences. For such tests, we counted, for a given 
motif, the number of motif matches in both the foreground and background sets of sequences and compared 
these values to one another. As many of the motif models are redundant, we used affinity propagation to cluster 
the motifs, using the pairwise Kullback-Leibler divergence as the similarity metric and a self-similarity parameter 
of −0.4. This procedure created 284 motif clusters. We post-clustered the motif enrichment results, retaining 
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the result from the most significantly enriched motif in each cluster, and corrected the raw p-values with the 
Benjamini-Hochberg procedure.
ChIP-Seq. Following overnight fasting, mice were anaesthetized and the liver was processed as previously 
described46. ChIP experiments were performed on two livers per condition (biological replicates) using anti-
bodies against RXRα (sc-153x, Santa Cruz Biotechnology, Santa Cruz, CA) or PPARα (MAB3890, Millipore, 
Billerica, MA). We fragmented chromatin with a Covaris S2 sonication machine (Covaris, Woburn, MA) to 
obtain fragments ranging from 500 to 1000 base pairs. 5 µg of antibody or IgG was incubated with beads for 
6 hours before incubating with sonicated chromatin overnight. We then washed the beads, eluted the chromatin, 
reversed crosslinks for 2 hours, and treated samples with RNase and Proteinase K. We purified the DNA and con-
structed sequencing libraries using the DNA Sample Kit (Part# 0801-0303, Illumina, San Diego, CA) according 
to the manufacturer’s instructions. The samples were sequenced on an Illumina GAII/HiSeq sequencing plat-
form and the resulting short reads were aligned against the mm9 reference mouse genome using Bowtie (version 
0.12.7)47. Enriched genomic regions were identified by MACS (version 1.4)48 using an IgG control and the result-
ing peaks were filtered to have an enrichment p-value of <1e-10. Overlapping peaks between RXRα and PPARα 
ChIP-Seq datasets were restricted to those whose summits mapped within ±100 bp. Transcription factor binding 
motifs from the TRANSFAC database were used with the THEME software package49 to find enriched motifs 
in the DNA sequences under the filtered ChIP peaks. For ChIP-Seq read pileup visualizations, we concatenated 
the aligned sequence reads from biological replicates for each factor in each condition, extracted reads mapping 
within the specified windows (allowing for only two reads mapping to the exact same location to minimize PCR 
biases), extended each read in the 3′ direction to a full length of 200 bp, summed the number of extended reads 
overlapping each base pair within the window, normalized the read count levels to account for sequencing depth 
differences between samples, and smoothed the read profiles using a moving average filter (120 bp rate). Thus, 
read pileup axes in Figs 3 and 5 refer to these concatenated, extended, normalized, and smoothed read profiles.
Primary hepatocytes. We isolated mouse primary hepatocytes with a modified 2-step perfusion method50 
that uses Liver Perfusion Media and Liver Digest Buffer (Invitrogen)51. We seeded cells on plates (pre-coated [1 h] 
rat tail collagen I [BD Biosciences]) in DMEM supplemented with 4.5 g/L glucose, 10% FBS, 0.2% BSA, 2 mM 
sodium pyruvate, 2 mM glutamine, 1 μM dexamethasone, 100 nM insulin and 1% penicillin/streptomycin. After 
attachment (2 h), the medium was removed and the hepatocytes were incubated (22 h) in maintenance medium 
(DMEM supplemented with 4.5 g/L glucose, 0.2% BSA, 2 mM sodium pyruvate, 2 mM glutamine, 0.1 µM dexa-
methasone, 1 nM insulin and 1% penicillin/streptomycin). In some cases, we incubated hepatocytes (16 h) with 
fenofibrate (100 μM, Sigma). The drugs were dissolved in DMSO; control studies were performed by addition of 
vehicle (DMSO) alone.
We evaluated glucose production by incubating 5.5 × 105 primary hepatocytes in collagen-coated 35 mm wells 
(6 well plates) with M199 media (Invitrogen) supplemented with 0.5% BSA and 1% penicillin/streptomycin for 
18 hours. Cells were then incubated in glucose/glutamine/phenol red-free DMEM (Sigma) supplemented with 
3.7 g/L sodium bicarbonate, 2 mM lactate and 20 mM sodium pyruvate for the indicated times. Glucose produc-
tion in the medium was assessed using the glucose (HK) assay kit (Sigma) and values were normalized to total 
hepatocyte protein.
We evaluated lactate production by incubating 5.5 × 105 primary hepatocytes in collagen-coated 35 mm wells 
(6 well plates) with M199 media (Invitrogen) supplemented with 0.5% BSA and 1% penicillin/streptomycin for 
18 hours. Cells were then incubated in glucose/glutamine/phenol red-free DMEM (Sigma) supplemented with 
1.85 g NaCl, 0.2% BSA, 0.1 µM dexamethasone, 1 nM insulin and 138 mM glucose for the indicated times. Lactate 
production was measured in the medium using the reconstituted Lactate Reagent (Beckman Coulter) and values 
were normalized to total hepatocyte protein.
Oxygen consumption rates. We quantified oxygen consumption rates (OCR) in primary hepatocytes 
using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA) and XF assay kits to measure 
extracellular flux changes of oxygen and protons. Briefly, primary hepatocytes were plated (4 × 104 cells/well) 
in collagen-coated XF24-microplates (Seahorse Bioscience). After attachment (2 h), the hepatocytes were trans-
ferred to running medium (sodium bicarbonate-free DMEM supplemented with 4.5 g/L glucose, 0.2% BSA, 2% 
penicillin/streptomycin, 1 nM insulin and 0.1 μM dexamethasone) and incubated at 37 °C in a humidified atmos-
phere without CO2 supplementation. Baseline measurements were performed prior to the addition of substrates 
(1 g/L glucose, 200 µM palmitate-BSA, or 10 mM lactate/1 mM pyruvate) or inhibitors (1 µM oligomycin, 0.1 µM 
FCCP, or 100 nM rotenone). Mitochondrial oxygen consumption rates were calculated as the difference between 
the maximal respiratory rate (in the presence of FCCP) and the respiratory rate after addition of rotenone. Data 
obtained from 11 independent wells were examined for each condition.
Quantitative RT-PCR. The expression of mRNA was examined by quantitative PCR using a Quantstudio 
PCR machine (Life Technologies). TaqMan® assays were used to quantify Acox1 (Mm01246834_m1), Ehhadh 
(Mm00619685_m1), Fbp1 (Mm00490181_m1), Gck (Mm00439129_m1), Pdk4 (Mm01166879_m1), and Pklr 
(Mm00443090_m1). The relative mRNA expression was normalized by measurement of the amount of 18S RNA 
in each sample using TaqMan© assays (catalog number 4308329; Life Technologies).
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